Zydus Cadila gets USFDA nod to sell hypertension drug

span.p-content div[id^=div-gpt] { line-height: 0px; font-size: 0px;} Cadila Healthcare today said its group firm has received the final approval from the US health regulator to market blood pressure medicine, Amlodipine and Olmesartan Medoxomil tablets.

The nod by US Food and Administration (USFDA) is for multiple strengths of the tablets 5mg/40mg; 10mg/20mmg and 10mg/40 mg, the company said in a filing.

"The is indicated for the treatment of hypertension, alone or with other anti-hypertensive agents to lower blood pressure and will be manufactured at the group's formulations manufacturing facility at Pharma SEZ Ahmedabad," Cadila Healthcare added.

The group has now more than 150 approvals and has so far filed over 300 abbreviated new applications (ANDAs) since the commencement of filing process in FY2003-04, it added.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Leave a Comment

Your email address will not be published. Required fields are marked *